News & Events
Highlights from ASH 2017 - Michael O'Dwyer talks about BCNI's CyborD-DARA study
Highlights from the American Society of Hematology meeting 2017 - BCNI's CyborD-DARA study
The World Myeloma Forum selected BCNI's Phase 1b CyborD-DARA study as one of the highlights of the American Society of Hematology (ASH)meeting in Atlanta in December.
See Prof Michael O'Dwyer talk about how weekly CyborD-Dara is a safe and effective upfront treatment for newly diagnosed multiple myeloma and the excellent progress being achieved in this study.